Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - atorvastatin calcium trihydrate, quantity: 86.76 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium carbonate; hyprolose; croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; polysorbate 80; titanium dioxide; macrogol 8000; hypromellose; purified talc - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1, pharmacodynamic properties, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin;   - film coated tablet - 10 mg - active: atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 21.7mg equivalent to 20 mg atorvastatin;   - film coated tablet - 20 mg - active: atorvastatin calcium 21.7mg equivalent to 20 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 43.4mg equivalent to 40 mg atorvastatin;   - film coated tablet - 40 mg - active: atorvastatin calcium 43.4mg equivalent to 40 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 86.8mg equivalent to 80 mg atorvastatin;   - film coated tablet - 80 mg - active: atorvastatin calcium 86.8mg equivalent to 80 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

United States - English - NLM (National Library of Medicine)

greenstone llc - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: in adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin

United States - English - NLM (National Library of Medicine)

h.j harkins company inc. - atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 40 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 prevention of cardiovascular disease in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets is indicated to: reduce the risk of myocardial infarction reduce the risk of stroke reduce the risk for revascularization procedures and angina in patients with type 2 diabetes, and without cli

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 10 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents